Lapatinib plus capecitabine for HER2-positive advanced-stage breast cancer in elderly women: Review of the anatolian society of medical oncology (ASMO) experience

Breast Care

Volumn 8, Issue 1, 2013, Pages 67-70

  Cetin, Bulent ^a,h   Benekli, Mustafa ^a   Dane, Faysal ^b   Boruban, Cem ^c   Gumus, Mahmut ^d   Oksuzoglu, Berna ^e   Kaplan, Mehmet A ^f   Tufan, Gulnihal ^a   Sevinc, Alper ^g   Coskun, Ugur ^a   Buyukberber, Suleyman ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c SELCUK UNIVERSITY   (Turkey)

^d DR LUTFI KIRDAR KARTAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^e Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital   (Turkey)

^f DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^g GAZIANTEP UNIVERSITY   (Turkey)

^h GAZI UNIVERSITY   (Turkey)

Author keywords

Advanced breast cancer; Capecitabine; Elderly women; HER2; Lapatinib

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB;

ABDOMINAL PAIN; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; LUNG METASTASIS; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STOMATITIS; VERY ELDERLY; VOMITING;

EID: 84875130150     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000346829     Document Type: Article

References (11)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182
2. Wildiers H, Kunkler I, Biganzoli L, et al.: Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007;8:1101-1115
3. Johnston S, Pippen J Jr, Pivot X, et al.: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-5546
4. Geyer CE, Forster J, Lindquist D, et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743
5. Cameron D, Casey M, Press M, et al.: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-543
6. Di Leo A, Gomez HL, Aziz Z, et al.: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26:5544-5552
7. Gomez HL, Doval DC, Chavez MA, et al.: Efficacy and safety of lapatinib as first-line therapy for Her2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005
8. Cetin B, Benekli M, Oksuzoglu B, et al.: Lapatinib plus capecitabine for brain metastases in patientswith human epidermal growth factor receptor 2-positive advanced breast cancer: A review of Anatolian Society of Medical Oncology (ASMO) experience. Onkologie 2012;35:740-745
9. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067
10. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAWA 2001;285:885-892
11. Capri G, Chang J, Chen SC, et al.: An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 2010;21:474-480.